

HB 364 -- ANTIPSYCHOTIC DRUGS

SPONSOR: Gregory (96)

Currently, the MO HealthNet Division within the Department of Social Services cannot impose any restrictions on access to individual atypical antipsychotic monotherapy for the treatment of schizophrenia, bipolar disorder, or psychosis associated with severe depression. This bill prohibits any restrictions on access for any antipsychotic medication.

The bill does not prohibit the Division from utilizing clinical edits to ensure clinical best practices.

Currently, the Division must issue a provider update at least twice a year to enumerate treatment and utilization principles for MO HealthNet providers. If the Division implements any new policy or clinical edit for an antipsychotic drug, the Division must continue to allow MO HealthNet participants access to any antipsychotic drug that they are using and are stable on or any drug that they have successfully used previously. The Division may recommend a resource list with no restrictions to access of antipsychotic drugs.

This bill removes several provisions from existing statute that:

- (1) Allow the Division to include considering cost in the context of best practices in its treatment and utilization principles for providers;
- (2) Outline the use of "nonpreferred" drugs; and
- (3) Limit available drugs for an individual patient.

This bill is similar to HB 1875 (2020) and HB 867 (2019).